^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Proleukin (aldesleukin)

    i
    Other names: rIL-2, recombinant human interleukin-2, 125-L-Serine-2-133-interleukin 2, r-serHuIL-2
    Company:
    Clinigen, Iovance Biotherap, Novartis
    Drug class:
    IL-2 stimulant, CD122 agonist
    Related drugs:
    1d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    7d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    18d
    19-C-0017: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
    P1/2, N=5, Completed, National Cancer Institute (NCI) | N=70 --> 5 | Recruiting --> Completed
    Trial completion • Enrollment change • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL
    22d
    NK4AML: Natural Killer-cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=9, Terminated, Radboud University Medical Center | N=23 --> 9 | Trial completion date: Sep 2025 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Jan 2026; Stop funding
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    IL15 (Interleukin 15) • IL7 (Interleukin 7)
    |
    cyclophosphamide • Proleukin (aldesleukin) • oNKord (inaleucel)
    1m
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    1m
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov)
    P3, N=1449, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    1m
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    New P1 trial • First-in-human
    |
    Proleukin (aldesleukin)
    1m
    CheckCell-2: CISH Inactivated TILs in the Treatment of NSCLC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Intima Bioscience, Inc. | N=70 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    PD-L1 negative
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Undisclosed CISH inactivated TIL
    1m
    2019LS002: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering (clinicaltrials.gov)
    P1/2, N=23, Completed, Intima Bioscience, Inc. | Trial primary completion date: Jan 2026 --> May 2025 | Active, not recruiting --> Completed
    Trial completion • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Undisclosed CISH inactivated TIL
    2ms
    A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (clinicaltrials.gov)
    P2, N=25, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    IL2 (Interleukin 2)
    |
    Proleukin (aldesleukin)
    2ms
    A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study (2025-522427-10-00)
    P1/2, N=10, Not yet recruiting, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
    New P1/2 trial
    |
    LDH elevation
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    2ms
    IOV-MEL-202: A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma (2025-522054-40-00)
    P1/2, N=69, Not yet recruiting, Iovance Biotherapeutics Inc.
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Amtagvi (lifileucel)